Literature DB >> 1916889

Human immunodeficiency virus (HIV)-infected cells and free virus directly activate the classical complement pathway in rabbit, mouse and guinea-pig sera; activation results in virus neutralization by virolysis.

G T Spear1, B L Sullivan, D M Takefman, A L Landay, T F Lint.   

Abstract

Since animal models of human immunodeficiency virus (HIV) infection are being used increasingly in determining various aspects of virus/host interaction and as models for virus expression, it will be important to assess any significant differences in anti-viral immune responses between animals and humans. Previous studies have shown that incubation of HIV with non-immune sera from several animal species results in virus neutralization, and that rabbit serum can lyse HIV-infected cells. The objectives of the current study were to evaluate the animal complement pathway(s) activated by HIV and HIV-infected cells and determine the mechanism by which complement could mediate viral neutralization. Incubation of HIV-infected cells with mouse, guinea-pig or rabbit sera resulted in cell-surface deposition of C3 fragments. Deposition of C3 fragments did not occur either in the presence of C4-deficient guinea-pig serum or in the absence of Ca2+, indicating that activation by infected cells occurred via the classical pathway. Neutralization of free virus was also mediated by the classical pathway since C4-deficient guinea-pig serum and Ca(2+)-chelated sera lacked activity. Serum treatment of virus resulted in release of HIV reverse transcriptase (RT), suggesting that neutralization occurred by C5b-9-mediated virolysis. RT was also released from simian immunodeficiency virus by animal complement. Antibodies in animal sera were not responsible for the classical pathway activation by free virus or HIV-infected cells. These results define several substantial differences between animal and human complement reactivity with HIV which could significantly affect the ability of HIV to replicate in animals, and which need to be considered in the assessment of animal models of HIV infection.

Entities:  

Mesh:

Year:  1991        PMID: 1916889      PMCID: PMC1384563     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

1.  Heat-labile, complement-like factor(s) of animal sera prevent(s) HIV-1 infectivity in vitro.

Authors:  S Hosoi; T Borsos; N Dunlop; P L Nara
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

2.  Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the proenzyme C1r2C1s2 complex, of the classical pathway of complement, without involvement of C1q.

Authors:  J H Lu; S Thiel; H Wiedemann; R Timpl; K B Reid
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

Review 3.  Complement and infectious agents: a tale of disguise and deception.

Authors:  N R Cooper; G R Nemerow
Journal:  Complement Inflamm       Date:  1989

Review 4.  The complement system: its importance in the host response to viral infection.

Authors:  R L Hirsch
Journal:  Microbiol Rev       Date:  1982-03

5.  Isolation of T-cell tropic HTLV-III-like retrovirus from macaques.

Authors:  M D Daniel; N L Letvin; N W King; M Kannagi; P K Sehgal; R D Hunt; P J Kanki; M Essex; R C Desrosiers
Journal:  Science       Date:  1985-06-07       Impact factor: 47.728

6.  Human T-cell leukaemia virus is not lysed by human serum.

Authors:  H Hoshino; H Tanaka; M Miwa; H Okada
Journal:  Nature       Date:  1984 Jul 26-Aug 1       Impact factor: 49.962

7.  Activation of complement on the surface of cells infected by human immunodeficiency virus.

Authors:  G T Spear; A L Landay; B L Sullivan; B Dittel; T F Lint
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

8.  Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome.

Authors:  F A Tausk; A McCutchan; P Spechko; R D Schreiber; I Gigli
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

9.  A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus.

Authors:  R A Ezekowitz; M Kuhlman; J E Groopman; R A Byrn
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

10.  Infection of rabbits with human immunodeficiency virus 1. A small animal model for acquired immunodeficiency syndrome.

Authors:  H Kulaga; T Folks; R Rutledge; M E Truckenmiller; E Gugel; T J Kindt
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

Review 2.  Complement and HIV-I infection/HIV-associated neurocognitive disorders.

Authors:  Fengming Liu; Shen Dai; Jennifer Gordon; Xuebin Qin
Journal:  J Neurovirol       Date:  2014-03-18       Impact factor: 2.643

Review 3.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

4.  Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin.

Authors:  Anja Fuchs; Tsai-Yu Lin; David W Beasley; Cordula M Stover; Wilhelm J Schwaeble; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2010-08-19       Impact factor: 21.023

Review 5.  In the Crosshairs: RNA Viruses OR Complement?

Authors:  Nisha Asok Kumar; Umerali Kunnakkadan; Sabu Thomas; John Bernet Johnson
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

6.  Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55).

Authors:  H Stoiber; C Pintér; A G Siccardi; A Clivio; M P Dierich
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

Review 7.  Viral mimicry of the complement system.

Authors:  John Bernet; Jayati Mullick; Akhilesh K Singh; Arvind Sahu
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.